Literature DB >> 15853583

Intracranial meningiomas: diagnosis and treatment.

Marc C Chamberlain1, Deborah T Blumenthal.   

Abstract

Meningiomas are extra-axial CNS tumors which have a female predominance and occur in middle-to-late adult life. Most meningiomas (90%) are benign, 6% are atypical and a small proportion (2%) are malignant. Most patients diagnosed with a meningioma undergo surgical resection to relieve neurological symptoms. Complete surgical resection is often curative. For most incompletely resected or recurrent tumors not previously irradiated, radiotherapy is administered. Radiotherapy may be administered as either conventional external beam irradiation or stereotactically by linear accelerator, gamma knife or cyberknife radiosurgery. Advocates of stereotactic radiotherapy have suggested this therapy in lieu of surgery particularly in poor surgical risk patients, patients with meningiomas in eloquent or surgically inaccessible locations and in patients of advanced age. When the meningioma is unresectable or all other treatments (e.g., surgery and radiotherapy) have failed, hormonal chemotherapy may be considered. Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15853583     DOI: 10.1586/14737175.4.4.641

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  15 in total

1.  A 44-year-old woman with a 3-month history of bilateral, painless visual loss in the absence of other symptoms.

Authors:  Emily H Shao; Kevin Gallagher; Nabeel Malik
Journal:  Digit J Ophthalmol       Date:  2012-12-31

2.  Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Authors:  Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez
Journal:  Histol Histopathol       Date:  2019-12-24       Impact factor: 2.303

3.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

Review 4.  Adult primary intradural spinal cord tumors: a review.

Authors:  Marc C Chamberlain; Trent L Tredway
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 5.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

Review 6.  Contemporary endovascular embolotherapy for meningioma.

Authors:  Gregory J Dubel; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

7.  Re-evaluation of cytostatic therapies for meningiomas in vitro.

Authors:  Annette Wilisch-Neumann; Doreen Pachow; Maren Wallesch; Astrid Petermann; Frank D Böhmer; Elmar Kirches; Christian Mawrin
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

Review 8.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

9.  Surgical Outcome of Treating Grades II and III Meningiomas: A Report of 32 Cases.

Authors:  Konstantinos Violaris; Vasileios Katsarides; Maria Karakyriou; Pavlos Sakellariou
Journal:  Neurosci J       Date:  2012-11-05

10.  Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.

Authors:  Melissa Schmidt; Andreas Mock; Christine Jungk; Felix Sahm; Anna Theresa Ull; Rolf Warta; Katrin Lamszus; Konstantinos Gousias; Ralf Ketter; Saskia Roesch; Carmen Rapp; Sebastian Schefzyk; Steffi Urbschat; Bernd Lahrmann; Almuth F Kessler; Mario Löhr; Christian Senft; Niels Grabe; David Reuss; Philipp Beckhove; Manfred Westphal; Andreas von Deimling; Andreas Unterberg; Matthias Simon; Christel Herold-Mende
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.